Medicinal Chemistry Research

, Volume 26, Issue 7, pp 1535–1549 | Cite as

Design and microwave facilitated green synthesis of 2-[4-(3-carboxymethyl, methoxy carbonylmethyl-2,4-dioxo and 4-oxo-2-thioxo-thiazolidin-5-ylidenemethyl)-phenoxy]-2 and 3-methyl propionic acid ethyl ester derivatives: a novel structural class of antidyslipidemic agents

  • Ashok Kumar Singh
  • Avinash C. Tripathi
  • Aseem Tewari
  • Viney Chawla
  • Shailendra K. Saraf
Original Research


An interesting hybrid molecular framework comprising of benzylidenethiazolidin-4-one, chalcone and fibrate was designed and synthesized (BRF112) in order to develop safe and efficacious compounds for the treatment of dyslipidemia, and related complications such as atherosclerosis. The synthesized derivatives were characterized by Fourier transform infrared spectroscopy, mass, and nuclear magnetic resonance spectral studies and evaluated for their antihyperlipidemic potential, using in vivo and in silico methods. All the synthesized compounds exhibited promising antidyslipidemic activity comparable to, and sometimes better than that of, the standard drug-fenofibrate at the tested dose of 30 mg/kg body weight. The most active compounds of the series, BRF4 and BRF6, demonstrated significant antidyslipidemic profile by lowering low density lipoprotein cholesterol, very low density lipoprotein cholesterol, and triglyceride and increasing the level of high density lipoprotein cholesterol, thereby decreasing the atherogenic index. Overall, these effects of BRF4 and BRF6 were found to be more potent than fenofibrate, in lipid lowering activity and reducing atherogenic index. Structure–activity relationship studies conclusively established that the presence of N-acetic acid methyl ester at 3rd position of the thiazolidin-4-one nucleus, and a C-3 fibric acid moiety at benzene nucleus were instrumental for enhanced biological activity. The binding mode of benzylidenethiazolidin-4-one fibrate class of compounds, showing crucial hydrogen bonds and pi–pi stacking interactions with the key amino acid residues Phe118, His440, and Tyr464 at the active site of PPARα receptor, was assessed by molecular docking studies.


Anti-hyperlipidemic Rhodanine Microwave assisted synthesis Molecular docking Benzylidenethiazolidin-4-one Fibrates 



We express our sincere gratitude to Central Drugs Research Institute (CDRI), Lucknow, India for providing the library and sophisticated analytical instrument facilities. Authors are thankful to the All India Council for Technical Education (AICTE), New Delhi, India, for providing grant under the Research Promotion Scheme (RPS), through which the computational software facility has been made available at the host institute. We also acknowledge the technical support team/application scientists of Schrodinger Inc. for their help during computational studies.

Conflict of interest

The authors declare that they have no competing interests.


  1. Adeghate E, Adem A, Hasan MY, Tekes K, Kalasz H (2011) Medicinal chemistry and actions of dual and pan PPAR modulators. Open Med Chem J 5:93–98CrossRefPubMedPubMedCentralGoogle Scholar
  2. Ashford M (2002) Assessmemt of biopharmaceutical properties. In: Aulton ME (ed) Pharmaceutics—the science of dosage form design, 2 edn. Churchill Livingstone, Edinburg, pp 257–258Google Scholar
  3. Balakumar P, Rose M, Ganti SS, Krishan P, Singh M (2007) PPAR dual agonists: are they opening Pandora’s Box? Pharmacol Res 56:91–98CrossRefPubMedGoogle Scholar
  4. Bruno G, Costantino L, Curinga C, Maccari R, Monforte F, Nicolo F, Ottana R, Vigorita MG (2002) Synthesis and aldose reductase inhibitory activity of 5-arylidene-2,4-thiazolidinediones. Bioorg Med Chem 10:1077–1084CrossRefPubMedGoogle Scholar
  5. da Costa Leite LF, Veras Mourao RH, de Lima Mdo C, Galdino SL, Hernandes MZ, de Assis Rocha Neves F, Vidal S, Barbe J, da Rocha Pitta I (2007) Synthesis, biological evaluation and molecular modeling studies of arylidene-thiazolidinediones with potential hypoglycemic and hypolipidemic activities. Eur J Med Chem 42:1263–1271CrossRefPubMedGoogle Scholar
  6. Fruchart JC (2009) Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease. Atherosclerosis 205:1–8CrossRefPubMedGoogle Scholar
  7. Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, Gurwitz JH, Chan KA, Goodman MJ, Platt R (2004) Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. Jama 292:2585–2590CrossRefPubMedGoogle Scholar
  8. Jeong TS, Kim JR, Kim KS, Cho KH, Bae KH, Lee WS (2004) Inhibitory effects of multi-substituted benzylidenethiazolidine-2,4-diones on LDL oxidation. Bioorg Med Chem 12:4017–4023CrossRefPubMedGoogle Scholar
  9. Lalloyer F, Staels B (2010) Fibrates, glitazones, and peroxisome proliferator-activated receptors. Arterioscler Thromb Vasc Biol 30:894–899CrossRefPubMedPubMedCentralGoogle Scholar
  10. Lee JS, Bok SH, Jeon SM, Kim HJ, Do KM, Park YB, Choi MS (2010) Antihyperlipidemic effects of buckwheat leaf and flower in rats fed a high-fat diet. Food Chem 119:235–240CrossRefGoogle Scholar
  11. Lehrke M, Lazar MA (2005) The many faces of PPARgamma. Cell 123:993–999CrossRefPubMedGoogle Scholar
  12. Mc Gill HC (1985) Geographical pathology of athersclerosis. Williams and Wilkins Co, BaltimoreGoogle Scholar
  13. Morphy R, Kay C, Rankovic Z (2004) From magic bullets to designed multiple ligands. Drug Discov Today 9:641–651CrossRefPubMedGoogle Scholar
  14. Pirat C, Farce A, Lebegue N, Renault N, Furman C, Millet R, Yous S, Speca S, Berthelot P, Desreumaux P, Chavatte P (2012) Targeting peroxisome proliferator-activated receptors (PPARs): development of modulators. J Med Chem 55:4027–4061CrossRefPubMedGoogle Scholar
  15. Quinn CE, Hamilton PK, Lockhart CJ, McVeigh GE (2008) Thiazolidinediones: effects on insulin resistance and the cardiovascular system. Br J Pharmacol 153:636–645CrossRefPubMedGoogle Scholar
  16. Rakowitz D, Maccari R, Ottana R, Vigorita MG (2006) In vitro aldose reductase inhibitory activity of 5-benzyl-2,4-thiazolidinediones. Bioorg Med Chem 14:567–574CrossRefPubMedGoogle Scholar
  17. Redemann CE, Icke RN, Alles GA (eds) (1955) Organic Synthesis vol 3. Organic Syntheses Inc., New York, WileyGoogle Scholar
  18. Rizos CV, Liberopoulos EN, Mikhailidis DP, Elisaf MS (2008) Pleiotropic effects of thiazolidinediones. Expert Opin Pharmacother 9:1087–1108CrossRefPubMedGoogle Scholar
  19. Sashidhara KV, Dodda RP, Sonkar R, Palnati GR, Bhatia G (2014) Design and synthesis of novel indole-chalcone fibrates as lipid lowering agents. Eur J Med Chem 81:499–509CrossRefPubMedGoogle Scholar
  20. Sashidhara KV, Palnati GR, Sonkar R, Avula SR, Awasthi C, Bhatia G (2013) Coumarin chalcone fibrates: a new structural class of lipid lowering agents. Eur J Med Chem 64:422–431CrossRefPubMedGoogle Scholar
  21. Shukla P, Srivastava SP, Srivastava R, Rawat AK, Srivastava AK, Pratap R (2011) Synthesis and antidyslipidemic activity of chalcone fibrates. Bioorg Med Chem Lett 21:3475–3478CrossRefPubMedGoogle Scholar
  22. Sortino M, Delgado P, Juarez S, Quiroga J, Abonia R, Insuasty B, Nogueras M, Rodero L, Garibotto FM, Enriz RD, Zacchino SA (2007) Synthesis and antifungal activity of (Z)-5-arylidenerhodanines. Bioorg Med Chem 15:484–494CrossRefPubMedGoogle Scholar
  23. Sundriyal S, Viswanad B, Ramarao P, Chakraborti AK, Bharatam PV (2008) New PPARgamma ligands based on barbituric acid: virtual screening, synthesis and receptor binding studies. Bioorg Med Chem Lett 18:4959–4962CrossRefPubMedGoogle Scholar
  24. Tiwari P, Puri A, Chander R, Bhatia G, Misra AK (2006) Synthesis and antihyperlipidemic activity of novel glycosyl fructose derivatives. Bioorg Med Chem Lett 16:6028–6033CrossRefPubMedGoogle Scholar
  25. Tripathi AC, Gupta SJ, Fatima GN, Sonar PK, Verma A, Saraf SK (2013) 4-Thiazolidinones: the advances continue. Eur J Med Chem 72C:52–77Google Scholar
  26. Tripathi P, Tripathi AC, Chawla V, Saraf SK (2014) Syntheses, characterization and evaluation of novel 2,6-diarylpiperidin-4-ones as potential analgesic-antipyretic agents. Eur J Med Chem 82:439–448CrossRefPubMedGoogle Scholar
  27. US Food and Drug Administration (2012) Statin drugs_drug safety communication class labelling change. Accessed Feb 2014
  28. Varga T, Czimmerer Z, Nagy L (2011) PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation. Biochim Biophys Acta 1812:1007–1022CrossRefPubMedPubMedCentralGoogle Scholar
  29. Verma A, Saraf SK (2008) 4-Thiazolidinone—a biologically active scaffold. Eur J Med Chem 43:897–905CrossRefPubMedGoogle Scholar
  30. Wierzbicki AS (2009) Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemia. Curr Opin Cardiol 24:372–379CrossRefPubMedGoogle Scholar
  31. Zhang HY (2005) One-compound-multiple-targets strategy to combat Alzheimer’s disease. FEBS Lett 579:5260–5264CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  1. 1.Department of Pharmaceutical Chemistry, Faculty of PharmacyBabu Banarasi Das Northern India Institute of TechnologyLucknowIndia

Personalised recommendations